CorneaGen Company Profile

Background

Overview

CorneaGen is a Seattle-based company dedicated to transforming corneal care through innovative medical devices, biologics, therapeutics, and interventions. Established in 2016 as a for-profit subsidiary of SightLife, CorneaGen aims to eliminate corneal blindness worldwide by 2040.

Mission and Vision

The company's mission is to provide the highest quality donor tissue, unparalleled customer service, and superior products that transform how ophthalmologists treat and care for every person impacted by corneal disease. CorneaGen envisions a world where corneal blindness is eradicated, and individuals have access to life-changing sight-restoring treatments.

Primary Area of Focus

CorneaGen specializes in the processing and delivery of high-quality donor corneal tissue for transplant surgeries. Additionally, the company develops and provides innovative surgical devices and technologies to enhance surgical efficiency and patient outcomes in corneal procedures.

Industry Significance

As the world's leading provider of ocular tissue, CorneaGen plays a pivotal role in addressing the global shortage of corneal donors. The company's innovations in tissue processing and surgical devices have significantly advanced corneal transplantation techniques, improving recovery times and visual acuity for patients.

Key Strategic Focus

Core Objectives

• Innovation in Corneal Care: Develop and introduce advanced medical devices, biologics, and surgical interventions to improve corneal transplantation outcomes.

• Global Expansion: Increase the availability of sight-restoring grafts worldwide, particularly in regions with limited access to donor tissue.

• Surgeon Support and Education: Provide comprehensive support to corneal surgeons through education, training, and access to cutting-edge surgical tools.

Specific Areas of Specialization

• Corneal Tissue Processing: Offer a range of tissue types, including standard full-thickness grafts, DMEK, and Nano-Thin™ DSEK, tailored to surgical requirements.

• Surgical Devices: Develop and supply devices like the EndoSerter®-PL and Geuder Pre-Loaded Glass Cannula to streamline surgical procedures.

• Corneal Cell Therapy: Advance treatments such as Corneal Tissue Addition for Keratoplasty (CTAK) and Cornea Cell Therapy to address corneal diseases with less invasive methods.

Key Technologies Utilized

• EndoSerter®-PL: A pre-loaded device designed to facilitate the delivery of Nano-Thin™ or Ultra-Thin DSEK grafts, enhancing surgical efficiency.

• Geuder Pre-Loaded Glass Cannula: A single-use system pre-loaded with DMEK tissue, pre-punched to a specified diameter, saving valuable time in the operating room.

• CTAK: A technique involving sterile, non-immunogenic corneal inlays to treat keratoconus, improving outcomes and surgical efficiency.

Primary Markets Targeted

• Corneal Surgeons and Surgery Centers: Provide high-quality tissue and innovative surgical devices to enhance surgical outcomes.

• Global Markets: Expand access to corneal transplants in nearly 50 countries, including Japan, through strategic partnerships and local collaborations.

Financials and Funding

Funding History

• October 2016: Secured initial funding of $10 million.

• April 2018: Additional funding raised; specific details not disclosed.

• October 2019: Completed a $37 million Series B financing round led by Flying L Partners, with participation from Falcon Vision and Petrichor Healthcare Capital Management.

Total Funds Raised

Approximately $47 million across multiple funding rounds.

Notable Investors

• Flying L Partners: Led the Series B financing round.

• Falcon Vision: Participated in the Series B round.

• Petrichor Healthcare Capital Management: Participated in the Series B round and provided a $25 million credit facility for global expansion.

Utilization of Capital

The funds have been allocated to:

• Product Development: Advancing Corneal Cell Therapy and other innovative treatments.

• Global Expansion: Establishing a subsidiary in Japan to obtain regulatory approval for manufacturing and commercialization.

• Operational Growth: Enhancing tissue processing capabilities and expanding partnerships with eye banks and surgical centers.

Pipeline Development

Key Pipeline Candidates

• Corneal Cell Therapy: A treatment involving the injection of cultured human eye endothelial cells into the anterior chamber of a corneal blind patient's eye, aiming to restore sight within a month and reduce the need for invasive corneal transplant surgery.

• CTAK: A technique using sterile, non-immunogenic corneal inlays to treat keratoconus, enhancing vision and comfort while maximizing the potential of donated tissue.

Stages of Development

• Corneal Cell Therapy: Clinical trials have been conducted in Japan, with patients reporting clear corneas one month post-procedure and sustained health over a year.

• CTAK: Launched in 2024, this technique offers advanced corneal contouring with patient-specific laser-cut tissue, gamma-irradiated for sterility and stability.

Target Conditions

• Corneal Cell Therapy: Corneal blindness due to endothelial cell dysfunction.

• CTAK: Keratoconus.

Anticipated Milestones

• Corneal Cell Therapy: Regulatory approval in Japan and potential expansion to other markets.

• CTAK: Wider adoption among corneal surgeons and integration into standard treatment protocols.

Technological Platform and Innovation

Proprietary Technologies

• EndoSerter®-PL: A pre-loaded device designed to facilitate the delivery of Nano-Thin™ or Ultra-Thin DSEK grafts, enhancing surgical efficiency.

• Geuder Pre-Loaded Glass Cannula: A single-use system pre-loaded with DMEK tissue, pre-punched to a specified diameter, saving valuable time in the operating room.

• CTAK: A technique involving sterile, non-immunogenic corneal inlays to treat keratoconus, improving outcomes and surgical efficiency.

Significant Scientific Methods

• Corneal Cell Therapy: Culturing human eye endothelial cells and injecting them into the anterior chamber of a corneal blind patient's eye to restore sight.

• CTAK: Using patient-specific laser-cut tissue to enhance corneal contouring and vision.

AI-Driven Capabilities

While specific AI-driven capabilities are not detailed in the available sources, CorneaGen's focus on innovation suggests potential integration of advanced technologies in their research and development processes.

Leadership Team

Key Executives

• Bernie Iliakis: President & CEO.

• Annie Thompson: Chief Financial Officer.

• John Guckes: Chief Executive Advisor.

• Bob Stevens: Senior VP of R&D.

Professional Backgrounds and Contributions

• Bernie Iliakis: As President & CEO, Bernie has been instrumental in guiding CorneaGen's strategic direction and fostering innovation in corneal care.

• Annie Thompson: Serving as CFO, Annie oversees financial operations, ensuring the company's fiscal health and supporting its growth initiatives.

• John Guckes: As Chief Executive Advisor, John provides strategic guidance, leveraging his extensive experience to steer the company's vision.

• Bob Stevens: Leading R&D, Bob drives the development of new technologies and treatments, maintaining CorneaGen's position at the forefront of corneal care innovation.

Leadership Changes

No significant leadership changes have been reported in the recent past.